OBJECTIVES:  Although, sorafenib is considered as the standard systemic therapy for HCC, its efficacy & safety profile needs to be further explored. This research aims to further explore the efficacy and safety of sorafenib in recently published trials in patients with advanced HCC. METHODS:  This review is an update to meta-analysis conducted by Pang et al. (2014). For the current analysis, PubMed and Cochrane databases were searched for randomized controlled trials (RCTs) published from 2013 to 2016. Randomized controlled trials which compared Sorafenib with other active comparators were selected as per pre-defined inclusion criteria. The outcomes included overall survival (OS), time to progression (TTP) and adverse event profile. Two reviewers independently extracted data from the included studies. Data was analysed using RevMan (v5.3). RESULTS:  Of the total 168 studies retrieved from database searches, three studies were included for data extraction and analysis with 1643 patients randomised to Sorafenib and 1621 patients randomised to comparator groups. Median overall survival with sorafenib ranged from 9.8 months to 10.2 months as compared to 7.9 months to 9.5 months with comparator groups. The median TTP was comparable with other groups and ranged from 3.8 months to 4.1 months with sorafenib. The overall adverse event profile of sorafenib was similar to comparator groups and grade 3/4 AE profile was significantly better than linifanib (p<0.001). The grade 3/4 AEs were more frequent with sunitinib and brivanib as compared to sorafenib. The results of meta-analysis will be presented in the poster as this is work-in-progress. CONCLUSIONS:  In advanced HCC, sorafenib had similar OS as compared to linifanib and brivanib. Further, sorafenib had significantly superior or equivalent OS to sunitinib. Safety results favored sorafenib in all the three trials.